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ABSTRACT 
The positive effect of vagus nerve stimulation (VNS) in patients with drug-resistant epilepsy is considered to be mediated by the 
afferent pathways of the vagus nerve, but the efferent pathways may influence the cardiac autonomic activity. 
Aim of the study. To assess the effects of VNS on cardiac autonomic modulation in epilepsy patients, over three months of 
neurostimulation.
Clinical rationale for the study. Linear and non-linear heart rate variability (HRV) analysis can provide information on the 
sympathovagal balance and reveal particularities of the central control of the autonomic cardiovascular function. 
Materials and Methods. Using Biopac Acquisition System, we analysed HRV parameters in resting condition and during sym-
pathetic and parasympathetic activation tests in five patients with drug-resistant epilepsy, who underwent VNS procedure.
Results. During the sympathetic and vagal activation tests, all five patients presented normal responses of cardiac autonomic 
activity, reflected in RMSSD, HFnu and LF/HF dynamics in both HRV evaluations. No bradycardia, cardiac arrhythmia or ortho-
static hypotension was registered during the two evaluations.
Conclusions. Our results indicate that VNS appears not to alter the cardiac autonomic function after three months of neurosti-
mulation. HRV analysis is a useful tool for evaluating cardiac autonomic modulation in epilepsy patients during VNS therapy. 
Clinical Implications. Patients with decreased HRV should be periodically monitored. Cardiac changes in patients with 
epilepsy are important because of the additional risk of arrhythmias mediated through the autonomic dysfunction. 
Key words: drug-resistant epilepsy, vagus nerve stimulation, cardiac autonomic modulation, heart rate variability, linear and 
non-linear analysis
(Neurol Neurochir Pol 2020; 54 (4): 329–336)
Introduction
Since vagus nerve stimulation (VNS) was approved as 
a therapeutic approach for the treatment of refractory epilepsy, 
the search has been ongoing for nonpharmacological modu-
lation of the autonomic nervous system (ANS) for different 
pathological conditions. The advantage of VNS therapy has 
also been evaluated for drug-resistant depression, heart failure, 
hypertension, and cardiac arrhythmias [1, 2].
The precise mechanism of neuromodulation exerted by 
the VNS is still a matter of debate. 80% of the fibres of the va-
gus nerve are afferent pathways to the central nervous system. 
Only 20% are efferent pathways, some of them reaching the 
cardiovascular system [3]. The afferent pathways of the vagus 
nerve play an essential role in the neuromodulation process, 
influencing the interplay of various cortical networks pro-
bably involved in epileptogenic activity [4, 5]. The activation 
of the vagal efferent pathways concerns the sinoatrial node 
and the cardiac conduction system [2, 4]. Consequently, it 
may decrease the heart rate and reduce atrioventricular 
conduction and excitability of the His bundle. 
Research dedicated to VNS’s impact on cardiac rhythm has 
yielded contradictory results. A minor increase in sympathetic 
cardiovascular modulation without significant haemodynamic 
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effects, probably related to the activation of sympathetic 
pathways from the brainstem, has been reported [3]. Cardiac 
bradyarrhythmia is a rare complication during ongoing VNS 
therapy [6]. An increase in cardiac vagal modulation appears 
to play a cardioprotective role against sudden death [7].
Heart rate variability (HRV) describes the variations be-
tween consecutive heartbeats, known as RR intervals, on ECG 
recordings. Frequency-domain analysis allows the assessment 
of the global variation of a biologic signal, divided into its 
different spectral components [8]. The presence of different 
frequency spectra can be attributed to the modulation of the 
ANS on cardiovascular activity [9–11]. Time-domain indices 
of HRV evaluate the amount of variability in measurements 
of the interbeat interval. Mechanisms involved in cardiova-
scular regulation interact with each other in a non-linear 
manner [12, 13]. Non-linear dynamics can be evaluated with 
the help of chaos theory, offering a more detailed perspective 
of the HRV. Fractal methods assess the scaling exponent of 
the signal which indicates the presence of fractal properties, 
or self-similarity of beat-to-beat intervals — the RR intervals 
on the ECG recordings [14]. Entropy measures have been 
widely used in HRV analysis, assessing the irregularity and 
complexity of HRV [15].
The rationale for implementing the analysis of the non-
-linear dynamics of HRV is thus to better understand the 
mechanisms of cardiac autonomic control. It has been demon-
strated that alteration of fractal properties precedes the onset of 
fatal cardiac arrhythmias [16], as the increased regularity and 
the loss of complexity in the heart rate signal is related to the 
dysregulation of cardiac autonomic control [17, 18]. A decre-
ased HRV was initially shown to be predictive of mortality in 
the elderly population [19]. Moreover, in epilepsy patients, 
it appears to be associated with an increased risk of sudden 
unexpected death (SUDEP) [20]. Therefore, HRV analysis may 
identify patients with autonomic dysregulation at risk of fatal 
cardiac arrhythmias [20]. 
The same group of patients was previously assessed using 
Multiple Trigonometric Regressive Spectral analysis, using 
a different analytical approach [21]. The actual evaluation 
based on Fast Fourier Transform provides, in addition to the 
spectral power analysis, the non-linear appraisal of the HRV. 
Since this has not been previously described [21], we consi-
dered it worthy of further analysis.
Clinical rationale for the study
The clinical rationale of this study was to assess the effects 
of VNS on cardiovascular autonomic function in different 
physiological conditions in drug-resistant epilepsy patients, 
over three months of neurostimulation. The results of the study 
may be clinically useful for detecting a cardiac activity adjust-
ment in the analysed epilepsy patients, and may contribute to 
better understanding of the effect of VNS on the autonomic 
cardiac activity.
Methods
ECG recordings of the first five patients with drug-resistant 
epilepsy who underwent VNS procedure, in our department, 
were analysed. In these patients, seizure control was not 
obtained within two years of multiple antiepileptic drug 
treatment. Epilepsy surgery was not a viable option in any of 
the five patients. Each patient had an ECG recording before 
VNS procedure and after three months of neurostimulation, 
during ON and OFF periods of the stimulation. All patients 
were monitored with prolonged EEG and ECG recordings 
before and after the autonomic tests (including night EEG), 
which excluded clinical or infraclinical seizures.
A standardised protocol consisting of a resting state ECG 
recording followed by four autonomic activation tests, each 
lasting for five minutes, was applied. Standardised conditions 
imposed the following criteria: ECG recording at the same 
time range after 30 minutes of clinostatism rest, in the absence 
of noise, at a constant temperature of 22°C, without previous 
physical activity or the ingestion of beverages containing caf-
feine. The four autonomic activation tests were performed in 
the same sequence in all patients, as follows: deep breathing, 
standing, hand-grip and Valsalva manoeuvre. To remove the 
respiratory influence on the heart rate, the patients followed 
a paced breathing pattern at 15 cycles per minute, as described 
in other studies [22]. During the deep breathing test, a comple-
te deep inhale and exhale lasted 10 seconds, six complete cycles 
per minute, to emphasise the vagal activation. The following 
sympathetic activation tests were performed: the standing test 
and the hand-grip test, consisting of a three-minute isometric 
contraction of the fist, using a dynamometer. BIOPAC® acqui-
sition system was used for the ECG recording. AcqKnowledge 
software version 3.9.1.6 eliminated artifacts of the recorded 
signal. HRV analysis was performed using Kubios HRV soft-
ware version 2.2 (Biosignal Analysis and Medical Imaging 
Group, University of Eastern Finland). HRV parameters were 
analysed using Fast Fourier Transform. A minimum of 256 RR 
intervals on the ECG were analysed for each recording.
The following HRV time-domain parameters were analy-
sed: Root Mean Square of the Successive Differences (RMSSD), 
the proportion of pairs of successive RR intervals that differ by 
more than 50 ms to the total number of NN intervals (pNN50), 
the standard deviation of the so-called normal-to-normal NN 
interval that reflects all the cyclic components responsible for 
variability in the period of recording (SDNN), the mean RR 
interval, and the heart rate [9]. The frequency-domain analysis 
referred to the following spectral components: VLF (very low 
frequency power, 0.02–0.04 Hz), LF (low frequency power, 
0.04–0.15 Hz) and HF (high frequency power, 0.15–0.4 Hz). 
These parameters were expressed in absolute values (ms2), 
and in relative values calculated as a percentage (%) to total 
power. Given the complex mechanisms that seem to influence 
the values  of the VLF spectrum (i.e. thermoregulatory mecha-
nisms, activity of the renin-angiotensin-aldosterone system) [9, 
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10], we analysed the normalised units (nu) for the LF and HF 
spectrum, which excluded from calculation VLF values, and 
the LF/HF ratio (the ratio of absolute LF power to HF power). 
RMSSD, pNN50, HF and HFnu parameters are considered 
to be markers of parasympathetic autonomic control on the 
heart rate [9, 10]. 
The following HRV parameters were considered for the 
non-linear analysis: SD1, SD2, SampEn (Sample Entropy), 
ApEn (Approximate Entropy), DFA α1 and DFA α2 (De-
trended Fluctuation Analysis α1 and α2). When analysing 
the Poincaré graph, SD1 shows the short-term variability of 
a chronological series, while SD2 is the second component 
of the ellipse formed from the point cloud (which has as 
abscissa and ordinate two consecutive R-R values from the 
ECG recording) and it illustrates the long-term variability 
of the biological signals [23]. SD1 represents the standard 
deviation of the Poincaré plot and is graphically perpendicular 
to the line-of-identity, while SD2 is along the line-of-identity. 
SD1 is considered a parameter that reflects the influence of 
parasympathetic tone on the control of the sinus node, being 
an expression of the rapid changes of the RR interval, since 
the vagal effects on the sinus node manifest faster than those 
mediated by the sympathetic nervous system [24, 25]. ApEn 
measures the ‘disorder’ in the heart rate signal and quantifies 
the regularity and complexity of the chronological series [26]. 
SampEn is a more constant measure derived from ApEn [27], 
which quantifies the complexity of the signal in short time seg-
ments [28], low values of SampEn indicating a greater similarity 
between successive RR in chronological series [29]. Detrended 
Fluctuation Analysis (DFA) is an evaluation method of the 
statistical ‘self-affinity’, assessing the regularity and complexity 
of the biosignals [27, 30, 31] when the RR interval is analysed. 
Values of the scalar exponent α that are higher than 1 illustrate 
an increase in regularity and a decrease in signal complexity in 
the chronological series [28, 29], with an increased self-correla-
tion power, constantly associated with pathological conditions 
[32, 33]. α1 represents the short-range scaling exponent, while 
α2 represents the long-range scaling exponent [14].
We referred mainly to the SD1, SampEn, ApEn and DFA 
α1 parameters, as our ECG recordings lasted five minutes.
All five patients underwent left laterocervical stimulation 
of the vagus nerve and had no cardiovascular comorbidities or 
cardiovascular medication. The output current of stimulation 
was 2 mA for the first, third and fourth patients, 1.5 mA for 
the second patient, and 1 mA for the fifth patient. The frequ-
ency of stimulation was set at 30Hz for all five patients, while 
pulse width (500 μsec), duty cycle (10%), ON time period 
(30 seconds) and OFF time period (5 minutes) was identical 
for all patients.
Biological parameters (blood pressure, oxygen saturation, 
renal and hepatic function and blood electrolytes) were wit-
hin the normal range for all five patients. The antiepileptic 
medication was unchanged either in the three months before 
the first ECG recordings or between the two HRV tests. Blood 
pressure was measured in supine and orthostatic position for 
each patient after both evaluations.
Patients were recruited from the neurological department, 
and all patients were duly informed according to the study 
protocol and consented to the assessment in accordance with 
ethical principles. This study was carried out in accordance 
with the Helsinki Declaration. 
For the statistical analysis of data, taking into consideration 
the small sample size, series normalisation was very difficult. 
Applied comparative tests were specific to the characteristics 
of the analysed parameters. A value of p < 0.05 was considered 
significant. GraphPad Prism software version 6.07 was used for 
the analysis and graphical presentation of the data.
Description of patients
The first patient, a 33-year-old female, was diagnosed with 
focal epilepsy (left anterior temporal epilepsy) and secondarily 
generalised seizures. The clinical symptoms were rotatory 
vertigo, breathing difficulties, facial flush, dreamy state, and ge-
neralisation. Brain MRI showed no abnormalities. The patient 
was being medicated with three antiepileptics: lamotrigine, 
levetiracetam and oxcarbazepine.
The second patient, a 34-year-old female, presented focal 
epilepsy (left insular epilepsy) with secondarily generalised sei-
zures. The clinical symptoms were nausea, dyspnoea, abnormal 
sensation of retrosternal pain, burning heat restricted to the 
perioral area, and anarthria. No epilepsy-related brain MRI 
abnormalities were found. The patient was under treatment 
with valproic acid and levetiracetam.
The third patient, a 34-year-old female, had been diagno-
sed with focal epilepsy (right insular epilepsy) and secondarily 
generalised seizures (rotatory vertigo, facial flush, sense of 
unreality, and subsequent generalisation) at the age of 22. 
No epilepsy-related brain MRI abnormalities. Patient under 
treatment with levetiracetam and oxcarbazepine.
The fourth patient, a 29-year-old female, presented multi-
focal epilepsy with secondarily generalised seizures (onset fea-
tures: vertigo, sweating and motor unilateral symptoms, motor 
aphasia and generalisation). Brain MRI showed parietal and 
occipital gyration abnormalities. Pharmacological treatment 
consisted of lamotrigine, levetiracetam and carbamazepine. 
The fifth patient, a 31-year-old male, presented left in-
sular focal epilepsy with secondarily generalised seizures 
(retrosternal ascending heat, hypersalivation and post-ictal 
psychomotor agitation with hetero-aggressive behaviour). Left 
insular atrophy with frontoparietal extension was revealed on 
cerebral MRI. Antiepileptic medication consisted of valproate 
and oxcarbazepine. 
Results
The first patient presented a sympathetic predominance on 
the heart rate control, as indicated by RMSSD, pNN50, HFnu 
and LF/HF values in resting state (Tab. 1). After the autonomic 
332
Neurologia i Neurochirurgia Polska 2020, vol. 54, no. 4
www.journals.viamedica.pl/neurologia_neurochirurgia_polska
activation tests, the patient displayed an appropriate response 
of the cardiac autonomic regulation, as marked by the values of 
HFnu and LF/HF. Parasympathetic activation tests increased 
the HRV, illustrated by DFAα1 values (Tab. 1). There was no 
significant difference concerning the dynamic of HFnu and LF/
HF parameters in response to activation tests in the two HRV 
evaluations (Fig. 1). After three months of neurostimulation, 
an improvement in HRV was noticed, as shown by an increase 
of ApEn and SampEn during standing test, hand-grip test and 
Valsalva manoeuvre (Fig. 1).
The second patient presented normal responses to pa-
rasympathetic and sympathetic activation tests, reflected in 
HFnu, LF/HF and RMSSD values during challenge, in both 
HRV evaluations. A decrease in the HRV after sympathetic 
activation tests in both evaluations was seen regarding DFA 
α1 values (Fig.1).
The third patient presented appropriate responses to 
parasympathetic and sympathetic activation tests mirrored 
in the dynamics of HFnu and LF/HF ratio in both HRV eva-
luations. DFAα1 presented similar values after three months 
of neurostimulation (Fig.1).
The fourth patient presented normal dynamic of the HFnu 
and LF/HF ratio in response to autonomic activation tests, 
similar in both HRV assessments. During sympathetic acti-
vation tests, there was a shift to sympathetic predominance, 
seen in LF/HF values, correlated with a low HRV after three 
months of neurostimulation, revealed by DFAα1 values (Fig.1).
For the fifth patient, during the first evaluation, the Val-
salva manoeuvre determined an increase of vagal modulation 
and of the HRV, illustrated by the values of RMSSD, pNN50, 
HFnu, SD1 and DFAα1 (Tab. 1). During the second evaluation, 
deep breathing test induced an increase in the parasympathetic 
control over the heart rate (higher RMSSD, HFnu values, lower 
LF/HF ratio), compared to resting state, highlighting a normal 
response to the vagal activation test. ApEn and SampEn illu-
strated similar responses to the activation tests in both HRV 
evaluations (Fig. 1).
All five patients presented an increase of vagal modulation 
after parasympathetic activation tests, specifically at the Val-
salva manoeuvre (p < 0.05), during the first HRV evaluation 
(T1) and after deep breathing test during the second HRV 
evaluation (T2), as shown by the RMSSD values (Fig. 2). LF/
HF ratio decreased after deep breathing test (p < 0.05) and 
Valsalva manoeuvre during the first HRV evaluation. The same 
dynamic of the LF/HF values was observed during the second 
HRV evaluation, with increased values after standing and 
hand-grip tests (p < 0.05) (Fig. 2). HFnu presented increased 
values after deep breathing test (p < 0.05) during the first HRV 
evaluation. Similar features were observed at the second HRV 
evaluation, with an increment of the HFnu values after deep 
breathing test and a decrease after sympathetic activation tests 
(p < 0.05), reflecting a regular response of the heart rate to 
sympathetic and parasympathetic modulation (Fig. 2). SDNN 
values presented a similar dynamic as RMSSD in response to 
the autonomic tests. Mean RR values were correlated to the 
heart rate values during the four autonomic tests (Tab. 1).
No patient presented orthostatic hypotension, defined as 
a decrease of at least 20 mmHg in systolic blood pressure or 
of at least 10mmHg in diastolic blood pressure, after a three-
-minutes standing test, performed after ECG recording, 
incurred after the two HRV evaluations. During autonomic 
evaluations and the prolonged ECG recordings, no cardiac 
arrhythmias were identified for the five patients. Furthermore, 
the patients did not recall seizure-related symptoms during 
the current hospitalisation. During the autonomic tests per-
formed, including the deep breathing test, the patients were 
not monitored by EEG, but no seizure was observed by the 
examiner or reported by the patient.
Discussion
The cortical neuromodulation exerted by VNS therapy 
involves brain structures related to autonomic regulation, such 
as the prefrontal region, thalamus and amygdala [34]. Recent 
findings indicate that activated vagal afferents initiate cen-
trally mediated reflexes that inhibit parasympathetic efferent 
outflows to the heart [35], without consequent bradycardia, 
a clinical feature not found in our five patients after VNS 
therapy. Efferent vagal fibres do not directly synapse with 
cardiomyocytes, but rather with the intrinsic cardiac nervous 
system, acting as a buffer in modulating the commands to the 
cardiomyocytes [35]. The intrinsic cardiac nervous system 
comprises a complex network of ganglia and its neurons that 
can independently operate or connect with its complement 
structures of the autonomic pathways in the spinal cord, 
brainstem or cortex, in order to balance the intracardiac 
reflexes [35]. 
Periodic VNS may effectively modulate heart rate dyna-
mics. A phenomenon of pharmacological tolerance has been 
described, in which both vagus nerve and the autonomic 
nervous network adapt to periodic stimulation [3].
Epilepsy and seizures can have dramatic effects on car-
diac function, through the ANS. While some authors have 
concluded that VNS seems not to change decreased HRV in 
drug-resistant epilepsy patients [35], others have reported 
that VNS improves HRV shortly after implantation via the 
extensive innervation of the vagus nerve into the sinoatrial 
and atrioventricular nodes [3, 8, 36]. However, cardiac auto-
nomic dysfunction related to VNS in epilepsy patients is rare 
(0.1%) [37–39]. 
The originality of our study consists of using the autonomic 
activation tests (Ewing tests) and the analysis of non-linear 
HRV parameters besides time- and frequency-domain para-
meters for describing the cardiac autonomic response after 
sympathetic and parasympathetic challenge in patients with 
drug-resistant epilepsy, three months after vagal stimulation. 
Non-linear parameters have been used to analyse and predict 
the behaviour of biological phenomena. These parameters 
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Table 1. Heart rate variability (HRV) parameters for the five patients
Test 1/ 
/Test 2
HR Mean RR SDNN RMSSD pNN50 LF (nu) HF (nu) LF/HF SD1 ApEn SampEn DFAα1
RS Patient 1 90/91 671/660 39/31 13/15 0.6/0.5 84.8/77.4 14.7/22.5 5.74/3.4 16/10 1.2/1.1 1.3/1.3 1.1/1.4
DB Patient 1 92/87 653/685 48/36 66/45 1.7/0.5 36.5/44.6 56.4/55 0.64/0.8 46.8/32 1.1/1 1.1/1 0.6/1.2
ST Patient 1 92/96 655/632 62/25 77/22 2.1/2.8 69/77 30/22 2.27/3.4 54.5/15 0.8/1.1 0.8/1.1 0.8/1.3
HG Patient 1 92/87 653/683 72/22 86/14 2.7/0.3 70/83.5 29/16.5 2.39/5 60/10.4 0.8/1.1 0.7/1.6 0.7/1.5
VA Patient 1 92/93 659/642 69/35 77/14 2.6/1 42.7/74.7 57.3/25.2 0.74/2.9 50/10.4 0.7/1 0.7/1 0.6/1.3
RS Patient 2 76/67 793/903 49/67 39/67 12/36 68/54.7 31/45.3 2.4/1.2 28/47 1.1/1 1.6/1.6 1.2/0.9
DB Patient 2 78/73 777/824 72/54 89/53 9.2/14.5 38.7/52.9 60.9/47 0.63/1.1 63/38 1/1 1/1.3 0.9/1.1
ST Patient 2 85/75 711/802 80/58 58/42 4.5/14.5 71/77 28/22 2.53/3.3 41/29 0.7/1 0.6/1.3 1.1/1.2
HG Patient 2 76/76 787/797 40/58 40/44 12.3/15.8 58/78.4 41.7/21.5 1.39/3.6 29/31 1.2/1.1 1.6/1.4 1.1/1.3
VA Patient 2 81/70 740/863 75/57 96/51 6.3/20 41/71 58.7/28.6 0.69/2.4 68/36 0.8/1 0.8/1.4 0.6/1.1
RS Patient 3 89/81 670/735 41/24 20/20 2.4/1.7 73.9/70 26/29.5 2.84/2.3 14/14 1/1.2 1.1/1.7 1.3/1.2
DB Patient 3 90/81 665/740 30/29 20/23 3.6/2.7 50/63.9 50/36 0.99/1.7 14/16 1/1.1 1.1/1.6 1.3/1.2
ST Patient 3 93/86 640/700 19/29 14/22 0.9/2.8 73/78 26/20 2.77/3.8 10/16 1.2/1.1 1.7/1.6 1.3/1.2
HG Patient 3 89/83 673/724 22/32 18/24 0.2/4.4 80/81.8 20/18.2 3.99/4.4 12.7/17 1.2/1 1.7/1.4 1.2/1.4
VA Patient 3 89/78 672/766 39/36 28/29 4.4/7 78/63 21/36 3.6/1.72 20/21 1/1 1.2/1.6 1.4/1.2
RS Patient 4 79/74 755/811 9/16 11/13.9 0.4/0.3 77/76 22/23 3.5/3.2 35/9 0.8/1.1 0.8/1.6 1/1.4
DB Patient 4 76/72 790/823 31/18 28/15 4/1.2 73/52 26.9/47 2.7/1.1 20/11 1/1.1 1.1/1.6 1.2/1.1
ST Patient 4 82/81 737/743 27/25 19/17 2.5/0.9 84/81 15/18 5.5/4.4 14/12 0.9/0.9 1.2/0.6 1.4/1.2
HG Patient 4 81/76 743/787 40/17 37/13 2.5/0.5 73.7/81 26.1/18 2.82/4.3 26/9 0.9/1.2 0.9/1.5 0.5/1.3
VA Patient 4 76/72 792/826 46/32 58/23 2.3/4.9 60.4/71 39.3/28 1.52/2.5 41/16 0.9/1 0.9/1.3 0.9/1.2
RS Patient 5 75/73 805/814 85/43 54/29.9 25/6.9 62/58.3 37/41.7 1.68/1.3 38.8/21 1/1.2 1.2/1.6 1.1/1
DB Patient 5 74/76 811/791 87/88 52/111.5 27/6.8 50.9/43.7 48.9/55 1.04/0.7 36.8/78 1/0.8 1.1/0.7 1.2/0.9
ST Patient 5 81/77 754/782 104/93 59.8/24.6 20.1/5.1 65.2/65.2 34.6/34.8 1.88/1.8 42.3/17 0.8/0.7 0.8/0.5 1.1/1.4
HG Patient 5 75/77 805/776 93/42 57.8/20.2 27.8/2.5 66.1/73.4 33.8/26.5 1.95/2.7 40.9/14 1/1 1.1/1.2 1.1/1.2
VA Patient 5 69/75 883/795 132/46 146/24.2 52.4/4.7 39.2/84.9 60.2/15.1 0.65/5.6 104/17 1.1/1 1.4/1.2 0.8/1.4
HR — heart rate; RR interval — variations between consecutive heartbeats; SDNN — standard deviation of Normal-to-Normal intervals; RMSSD — Root Mean Square of Successive Differences; 
pNN50 — the proportion of NN50, representing the number of pairs of successive NNs that differ by more than 50 ms, divided by total number of NNs; LF — low frequency power; HF — high 
frequency power; ApEn — Approximate Entropy; SampEn — Sample Entropy; SD1 – standard deviation of instantaneous beat-to-beat interval variability; DFA – detrended fluctuation analysis
have proved to be good predictors of morbidity and mortality 
in clinics [40]. 
Although it is known that drug-resistant epilepsy is asso-
ciated with significant inhibition of vagal modulation of heart 
rate and lower HRV [41, 42], the non-linear parameters ApEn, 
SampEn, SD1 underlined an increase of HRV during the va-
gal activation tests compared to sympathetic activation tests. 
DFA α1 confirmed the increase of HRV, especially during the 
Valsalva test, in all five patients, in the first evaluation. Thus, 
the non-linear analysis of HRV validated the results from 
time- and frequency-domain analysis, reflecting the shift in 
the sympathovagal balance during the autonomic tests. 
VNS appears not to disrupt the cardiac autonomic acti-
vity, with no significant alteration in HRV parameters during 
autonomic tests being registered during the ECG recordings. 
The first and fourth patients presented sympathetic predomi-
nance over the heart rate control. The first patient displayed an 
increase of HRV, while the fourth patient displayed a decrease 
of HRV requiring further cardiac monitoring. Also, the se-
cond patient presented a decrease of HRV after sympathetic 
activation tests in both evaluations, while the third and the 
fifth patients kept constant features regarding the non-linear 
parameters. This observation underlines the importance of 
non-linear analysis, which may provide useful information 
about the cardiac autonomic state. 
Our results reveal that all patients presented adequate 
autonomic responses after sympathetic and parasympathetic 
activation tests, before VNS therapy, and three months after 
neurostimulation.
Although not necessarily reflecting a novel mechanism, 
the dynamic autonomic tests provide useful information 
regarding cardiac regulation. An impaired response to the 
autonomic challenge reflected by HRV parameters is not only 
a potential biomarker for monitoring progressive decline of the 
ANS system regulation, but is also a probable risk factor for 
sudden unexplained death determined by cardiac arrhythmias 
in patients with epilepsy [20, 43]. 
Further studies are needed to assess whether a perpetu-
ation of the sympathetic control and a decreased HRV, ob-
served in some of our patients during sympathetic activation 
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Figure 1. Heart rate variability (HRV) parameters for the five patients
tests, is confirmed in larger populations of drug-resistant 
epilepsy patients during VNS therapy, and if it might pre-
dispose to negative outcomes in patients with concurrent 
diseases. Currently, there is insufficient data to show how VNS 
influences different cardiac autonomic activity parameters 
within 24 hours, implying sleep-wake alternation, including 
physiological vulnerability periods of cardio-circulatory or 
respiratory control.
HRV analysis may be included in the current drug-
-resistant epilepsy patient evaluation. Drug-resistant epilepsy 
patients who are non-responders to VNS therapy, defined as 
the lack of an at least 50% seizure reduction after one year of 
treatment, had significantly lower RMSSD, pNN50, HF, and 
SD1 than the responders [44]. Thus, presurgical HRV evalu-
ation measurements representing parasympathetic control on 
heart rate were significantly associated with the responsiveness 
to VNS [44] and may serve as a marker for the effectiveness of 
this therapeutic option, although further studies are needed 
to evaluate this hypothesis.
VNS has been shown to exert antiarrhythmic effects, 
improve left ventricular function, and reduce mortality in pa-
tients with heart failure [45]. The optimum VNS parameters 
define a stabilised state in which both afferent and efferent 
fibres are activated in a balanced manner, called ‘neural ful-
crum’ [35]. VNS performed near this neural fulcrum ensures 
an adequate response to stressors involving both central 
and peripheral components [35]. It would be of interest to 
analyse whether reaching this cardiac autonomic balanced 
state would reduce the risk of fatal cardiac arrhythmia in 
epilepsy patients. 
HRV study could, therefore, provide essential data about 
the neural fulcrum and could guide the adjustments of VNS 
parameters for the neurological target as well.
One limit of our study, besides the limited number of 
patients, is the interfering antiepileptic medication, especial-
ly sodium or potassium channel blockers that may alter the 
depolarisation-repolarisation potentials of the cardiac cells. It 
is therefore difficult to distinguish the medication-mediated 
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Figure 2. Root Mean Square of the Successive Differences (RM-
SSD), low frequency power (LF)/ high frequency power (HF) ratio 
and HFnu dynamics for the five patients
effects from the cardiac dysautonomia present in epilepsy 
patients. 
Clinical implications and future directions
The involvement of ANS in patients with epilepsy has been 
insufficiently explored, and has produced conflicting results. 
Epilepsy patients present a risk of sudden unexpected death, 
autonomic dysfunction being one of the causes. However, the 
exact mechanism remains unclear. HRV is a useful method to 
assess the influence of ANS at the cardiac level.
Our results revealed that VNS does not alter the cardiac 
autonomic responses to the sympathetic and parasympathetic 
activation tests, having no clinically relevant effects on cardiac 
autonomic activity at the analysed stimulation threshold. 
Patients with decreased HRV should be periodically mo-
nitored. Further studies on larger groups of drug-resistant 
epilepsy patients, and longer follow-up periods, are needed 
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